Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease

L. Priano, G. Albani, S. Calderoni, S. Baudo, L. Lopiano, M. Rizzone, V. Astolfi, R. Cavalli, M. R. Gasco, F. Fraschini, B. Bergamasco, A. Mauro

Research output: Contribution to journalArticlepeer-review


This study evaluated the efficacy in Parkinson's disease (PD) of a new pharmacologic preparation of apomorphine included in microemulsions and administered by transdermal route, which provides a constant release of the drug for several hours (Apo-TD). Twenty-one PD patients with motor fluctuations were treated with L-dopa alone, with L-dopa plus oral dopamine-agonists, or with L-dopa plus Apo-TD. Apo-TD improved UPDRS-III and tapping test scores in "off" conditions, and reduced duration of "off" periods; no improvement in "on" conditions occurred. We conclude that Apo-TD shows its efficacy particularly by reducing "off" period duration and disability rather than improving motor performances in "on" conditions and therefore it seems a promising treatment for uncontrolled "off" phases in PD patients.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 2
Publication statusPublished - Sep 2002

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease'. Together they form a unique fingerprint.

Cite this